Reactions 1680, p295 - 2 Dec 2017 Various toxicities: 10 case reports A retrospective study described 10 patients (including a 40-year-old woman) [ages and sexes of other patients not stated], who developed anaemia, anorexia, diarrhoea, hand- foot skin reaction, hypertension, hypoalbuminaemia, hypophosphataemia, hypothyroidism, malaise, neutropenia, proteinuria, thrombocytopenia, weight loss or increased lipase during treatment with regorafenib [time to reactions onsets not stated]. All the ten patients had a medical history of unresectable hepatocellular carcinoma. All the patients had undergone a prior treatment with sorafenib which was discontinued due to disease progression. Later, all the ten patients were started on treatment with oral regorafenib 160mg once daily for 3 weeks in each 4 week cycle with best supportive care. Subsequently, they developed grade 2 hypoalbuminaemia, grade 3 hypophosphataemia, grade 2 weight loss and grade 2 anorexia (1 patient); grade 3 hand-foot skin reaction and grade 3 hypertension (1 patient); grade 2 proteinuria and grade 2 malaise (1 patient); grade 2 anorexia and grade 3 lipase increased (1 patient); grade 3 proteinuria, grade 3 hypertension, grade 2 hypothyroidism, grade 2 anorexia, grade 2 anaemia, grade 3 hypophosphataemia or grade 2 thrombocytopenia (1 patient); grade 2 diarrhoea and grade 2 anorexia (1 patient); grade 2 malaise and grade 1 anorexia (1 patient); grade 2 thrombocytopenia or grade 3 neutropenia (1 patient); grade 1 hand-foot skin reaction, grade 2 malaise, grade 3 thrombocytopenia and grade 3 neutropenia (1 patient), and one patient developed grade 3 hand-foot skin reaction. All treatment-related adverse events were improved by the reduction or interruption of regorafenib treatment. Author comment: "In this study, we investigated the efficacy and safety of regorafenib". "The drug-related adverse events are summarized. . . Grade 3 hypophosphatemia without symptoms was observed in 2 patients, grade 2 anorexia was observed in 5 patients, and grade 3 neutropenia was observed in 2 patients. Grade 2 and grade 3 thrombocytopenia were observed in 2 and 3 patients, respectively." Ueshima K, et al. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience. Digestive Diseases 35: 611-617, No. 6, Oct 2017. Available from: URL: http://doi.org/10.1159/000480257 - Japan 803285178 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera